WO2018174408A8 - 항-dr5 항체 및 그의 용도 - Google Patents

항-dr5 항체 및 그의 용도 Download PDF

Info

Publication number
WO2018174408A8
WO2018174408A8 PCT/KR2018/001711 KR2018001711W WO2018174408A8 WO 2018174408 A8 WO2018174408 A8 WO 2018174408A8 KR 2018001711 W KR2018001711 W KR 2018001711W WO 2018174408 A8 WO2018174408 A8 WO 2018174408A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antigen
binding fragment
cancer cells
present
Prior art date
Application number
PCT/KR2018/001711
Other languages
English (en)
French (fr)
Other versions
WO2018174408A1 (ko
Inventor
도현미
이동섭
이한영
김유진
한경미
정은이
김동현
송동섭
신금주
우소연
Original Assignee
동아에스티 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동아에스티 주식회사 filed Critical 동아에스티 주식회사
Priority to RU2019131014A priority Critical patent/RU2735956C1/ru
Priority to AU2018239725A priority patent/AU2018239725B2/en
Priority to BR112019019505-0A priority patent/BR112019019505A2/pt
Priority to CN201880020143.5A priority patent/CN110637032B/zh
Priority to US16/492,780 priority patent/US11840574B2/en
Priority to CA3056202A priority patent/CA3056202C/en
Priority to EP18772434.9A priority patent/EP3613769A4/en
Priority to JP2019552166A priority patent/JP7080896B2/ja
Publication of WO2018174408A1 publication Critical patent/WO2018174408A1/ko
Publication of WO2018174408A8 publication Critical patent/WO2018174408A8/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

세포사멸 수용체 5(death receptor 5； DR5)에 특이적으로 결합하여 암세포 사멸 기능을 갖는 항체와 관련된 것으로, 구체적으로 항 -DR5 항체 또는 이의 항원결합단편, 및 상기 항체 또는 항원결합단편의 암의 예방 또는 치료 용도가 제공된다. 상기 항 -DR5 항체 또는 이의 항원결합단편은 DR5에 대한 친화도 및 안정성 및 암세포 사멸 효과가 개선된 것을 특징으로 한다.
PCT/KR2018/001711 2017-03-21 2018-02-08 항-dr5 항체 및 그의 용도 WO2018174408A1 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
RU2019131014A RU2735956C1 (ru) 2017-03-21 2018-02-08 Анти-dr5-антитело и его применение
AU2018239725A AU2018239725B2 (en) 2017-03-21 2018-02-08 Anti-DR5 antibody and use thereof
BR112019019505-0A BR112019019505A2 (pt) 2017-03-21 2018-02-08 Anticorpo anti-dr5 e a utilização do mesmo
CN201880020143.5A CN110637032B (zh) 2017-03-21 2018-02-08 抗dr5抗体及其用途
US16/492,780 US11840574B2 (en) 2017-03-21 2018-02-08 Anti-DR5 antibody and use thereof
CA3056202A CA3056202C (en) 2017-03-21 2018-02-08 Anti-dr5 antibody and use thereof
EP18772434.9A EP3613769A4 (en) 2017-03-21 2018-02-08 ANTI-DR5 ANTIBODIES AND ASSOCIATED USE
JP2019552166A JP7080896B2 (ja) 2017-03-21 2018-02-08 抗ｄｒ５抗体およびその用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170035623A KR101926834B1 (ko) 2017-03-21 2017-03-21 항-dr5 항체 및 그의 용도
KR10-2017-0035623 2017-03-21

Publications (2)

Publication Number Publication Date
WO2018174408A1 WO2018174408A1 (ko) 2018-09-27
WO2018174408A8 true WO2018174408A8 (ko) 2019-08-22

Family

ID=63586386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/001711 WO2018174408A1 (ko) 2017-03-21 2018-02-08 항-dr5 항체 및 그의 용도

Country Status (10)

Country Link
US (1) US11840574B2 (ko)
EP (1) EP3613769A4 (ko)
JP (1) JP7080896B2 (ko)
KR (1) KR101926834B1 (ko)
CN (1) CN110637032B (ko)
AU (1) AU2018239725B2 (ko)
BR (1) BR112019019505A2 (ko)
CA (1) CA3056202C (ko)
RU (1) RU2735956C1 (ko)
WO (1) WO2018174408A1 (ko)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
KR100847010B1 (ko) 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
WO2010047509A2 (ko) * 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2010138725A1 (en) 2009-05-28 2010-12-02 Amgen Inc. Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2012057288A1 (ja) 2010-10-29 2012-05-03 第一三共株式会社 新規抗ｄｒ５抗体
CN102898524A (zh) 2011-07-25 2013-01-30 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体受体dr5的人-鼠嵌合抗体及其制法与用途
MX350202B (es) 2012-03-28 2017-08-30 Amgen Inc Combinaciones de agonistas de receptores de muerte 5 (dr5).
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
WO2014063368A1 (zh) 2012-10-26 2014-05-01 中国医学科学院基础医学研究所 抗人死亡受体5胞外区的人源化单克隆抗体
US10077316B2 (en) * 2013-12-27 2018-09-18 National University Corporation, Kochi University Esophageal cancer marker and use thereof
SG11201706024YA (en) * 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
EP3337505A4 (en) 2015-08-19 2019-02-27 Sinotau Pharmaceuticals Group TRAIL-RECEPTOR BINDING AGENTS AND USES THEREOF

Also Published As

Publication number Publication date
CA3056202A1 (en) 2018-09-27
CA3056202C (en) 2022-01-18
EP3613769A1 (en) 2020-02-26
CN110637032A (zh) 2019-12-31
US11840574B2 (en) 2023-12-12
JP7080896B2 (ja) 2022-06-06
JP2020513833A (ja) 2020-05-21
CN110637032B (zh) 2023-05-12
KR20180106771A (ko) 2018-10-01
RU2735956C1 (ru) 2020-11-11
WO2018174408A1 (ko) 2018-09-27
KR101926834B1 (ko) 2018-12-07
EP3613769A4 (en) 2021-04-14
BR112019019505A2 (pt) 2020-05-26
AU2018239725A1 (en) 2019-10-17
AU2018239725B2 (en) 2021-03-18
US20230133381A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
MX2024005811A (es) Inmunoglobulinas de enlace a tgf?1 y usos de las mismas.
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
WO2016191643A3 (en) Tigit-binding agents and uses thereof
MX2017017144A (es) Anticuerpos de factor xi y metodos de uso.
WO2018031490A3 (en) Anti-ox40 binding proteins
WO2017136659A3 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
EA201890578A1 (ru) Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2020002406A (es) Anticuerpo anti-epha4.
WO2019028182A3 (en) TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2024003627A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso.
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA202092265A1 (ru) Антитела против cd137 для комбинации с антителами против pd-l1
WO2018174408A8 (ko) 항-dr5 항체 및 그의 용도
WO2016073647A3 (en) COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
WO2020252478A3 (en) Antibodies against pd-1 and methods of use thereof
MX2020013923A (es) Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18772434

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019552166

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019019505

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018239725

Country of ref document: AU

Date of ref document: 20180208

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018772434

Country of ref document: EP

Effective date: 20191021

ENP Entry into the national phase

Ref document number: 112019019505

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190919